Sector News

Stryker acquires single-use device reprocessor Hygia Health Services

May 2, 2018
Life sciences

Stryker said today it acquired single-use-device reprocessor Hygia Health Services for an undisclosed amount.

Birmingham, Ala.-based Hygia has partnered with Kalamazoo, Mich.-based Stryker since 2015 to reprocess single-use devices, and Stryker said the acquisition will “further solidify the partnership.”

Stryker said that Hygia’s product portfolio of air transfer mattresses, fall alarms, ECG leads, cerebral-somatic sensors and infusor bags will help broaden its reprocessing offerings. Stryker said that it reprocessed approximately 3,000 single-use devices in 2017, with estimated savings of approximately $326 million.

“In line with our commitment to help hospitals and health systems increase the value their SUD reprocessing programs deliver, this acquisition will enhance our ability to deliver savings to our customers. Furthermore, our broader product portfolio will help customers elevate their sustainability goals and set a higher bar for sustainable healthcare delivery,” Stryker sustainability solutions prez Brian White said in a prepared statement.

Last week, Stryker saw shares fall slightly after it posted first quarter earnings that topped Wall Street expectations but saw sales shrink slightly.

By Fink Densford

Source: MassDevice

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.